bioAffinity Technologies Executes Agreement with Fosun Long March to Evaluate CyPath® Lung for Commercialization in China
Retrieved on:
Thursday, February 4, 2021
Shanghai Fosun Long March Medical Science Co., Ltd. (Fosun Long March) has executed a non-binding Letter of Intent (LOI) with bioAffinity Technologies, Inc. providing for Fosun to evaluate CyPath Lung, a non-invasive test for the early detection of lung cancer, with an expectation of negotiating and entering into binding agreements to commercialize the early lung cancer diagnostic in China.
Key Points:
- Shanghai Fosun Long March Medical Science Co., Ltd. (Fosun Long March) has executed a non-binding Letter of Intent (LOI) with bioAffinity Technologies, Inc. providing for Fosun to evaluate CyPath Lung, a non-invasive test for the early detection of lung cancer, with an expectation of negotiating and entering into binding agreements to commercialize the early lung cancer diagnostic in China.
- Fosun Long March is a wholly owned company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( Fosun Pharma , stock code: 02196.HK; 600196.SH).
- We look forward to proceeding with the collaboration with bioAffinity Technologies and working together to launch CyPath Lung in China.
- We are very excited to be working with Fosun Long March in advancing CyPath Lung.